{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:39:54Z","timestamp":1793353194021,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019854","name":"Greater Copenhagen Health Science Partners","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF19OC0056411"],"award-info":[{"award-number":["NNF19OC0056411"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cmi.2025.08.012","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:56:53Z","timestamp":1755741413000},"page":"2011-2017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Change in pulmonary pathogens 3 years after elexacaftor\/tezacaftor\/ivacaftor: an observational study in the Danish cystic fibrosis cohort"],"prefix":"10.1016","volume":"31","author":[{"given":"Maria Pals","family":"Bendixen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majbritt","family":"Jeppesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oihane","family":"Irazoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Bj\u00f8rn","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikala","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terese Lea","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tacjana","family":"Pressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Vebert","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Jensen-Fangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tavs","family":"Qvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle Krogh","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.08.012_bib1","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1073\/pnas.88.15.6565","article-title":"Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis","volume":"88","author":"Trapnell","year":"1991","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.cmi.2025.08.012_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1146\/annurev.physiol.68.072304.112754","article-title":"Regulation of normal and cystic fibrosis airway surface liquid volume by phasic shear stress","volume":"68","author":"Tarran","year":"2006","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.cmi.2025.08.012_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcf.2024.04.015","article-title":"Widespread alterations in systemic immune profile are linked to lung function heterogeneity and airway microbes in cystic fibrosis","volume":"23","author":"Rossi","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.cmi.2025.08.012_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ng.3148","article-title":"Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis","volume":"47","author":"Marvig","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.cmi.2025.08.012_bib5","first-page":"00914","article-title":"Within-host evolution of Pseudomonas aeruginosa reveals adaptation toward iron acquisition from hemoglobin","volume":"00966","author":"Marvig","year":"20145","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2025.08.012_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41467-019-08504-7","article-title":"Evolutionary highways to persistent bacterial infection","volume":"10","author":"Bartell","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2025.08.012_bib7","doi-asserted-by":"crossref","first-page":"2000512","DOI":"10.1183\/13993003.00512-2020","article-title":"Omics-based tracking of Pseudomonas aeruginosa persistence in \u201ceradicated\u201d cystic fibrosis patients","volume":"57","author":"Bartell","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2025.08.012_bib8","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1513\/AnnalsATS.202210-852OC","article-title":"The clinical association between Aspergillus fumigatus and respiratory outcomes in adolescents and adults with cystic fibrosis","volume":"20","author":"O\u2019Dea","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.cmi.2025.08.012_bib9","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s10096-015-2474-y","article-title":"Aspergillus fumigatus chronic colonization and lung function decline in cystic fibrosis may have a two-way relationship","volume":"34","author":"Noni","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.012_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/mmy\/myv119","article-title":"Chronic Aspergillus fumigatus colonization of the pediatric cystic fibrosis airway is common and may be associated with a more rapid decline in lung function","volume":"54","author":"Saunders","year":"2016","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2025.08.012_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.cmi.2025.08.012_bib12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment","volume":"338","author":"Valerius","year":"1991","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.cmi.2025.08.012_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/apm.13375","article-title":"Close monitoring and early intervention: management principles for cystic fibrosis in Denmark","volume":"132","author":"Qvist","year":"2024","journal-title":"APMIS"},{"key":"10.1016\/j.cmi.2025.08.012_bib14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/apm.12915","article-title":"Cystic fibrosis\u2014an example of personalized and precision medicine","volume":"127","author":"Skov","year":"2019","journal-title":"APMIS"},{"key":"10.1016\/j.cmi.2025.08.012_bib15","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.012_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2025.08.012_bib17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.08.012_bib18","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.08.012_bib19","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health - Eur"},{"key":"10.1016\/j.cmi.2025.08.012_bib20","doi-asserted-by":"crossref","first-page":"00339","DOI":"10.1183\/23120541.00339-2024","article-title":"Lung function improvement on triple modulators\u2014high-resolution nationwide data from the Danish cystic fibrosis cohort","volume":"10","author":"Leo-Hansen","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.cmi.2025.08.012_bib21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/apm.13453","article-title":"Real-world data confirm elexacftor\/tezacaftor\/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis","volume":"132","author":"Bryrup","year":"2024","journal-title":"APMIS Acta Pathol Microbiol Immunol Scand"},{"key":"10.1016\/j.cmi.2025.08.012_bib22","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cmi.2025.08.012_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.cmi.2025.08.012_bib24","doi-asserted-by":"crossref","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2025.08.012_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcf.2023.10.010","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on mucus and mucociliary clearance in cystic fibrosis","volume":"23","author":"Donaldson","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cmi.2025.08.012_bib26","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jcf.2021.11.003","article-title":"A restructuring of microbiome niche space is associated with elexacaftor-tezacaftor-ivacaftor therapy in the cystic fibrosis lung","volume":"21","author":"Sosinski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cmi.2025.08.012_bib27","first-page":"100829","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir Med Res"},{"key":"10.1016\/j.cmi.2025.08.012_bib28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","volume":"139","author":"Dittrich","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2025.08.012_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00519-24","article-title":"Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis","volume":"15","author":"Armbruster","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2025.08.012_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184171","article-title":"Elexacaftor\/tezacaftor\/ivacaftor\u2019s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment","volume":"134","author":"Morgan","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cmi.2025.08.012_bib31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jcf.2008.06.009","article-title":"Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 Years experience","volume":"7","author":"Hansen","year":"2008","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cmi.2025.08.012_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jcf.2008.02.003","article-title":"Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients","volume":"7","author":"Johansen","year":"2008","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cmi.2025.08.012_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/pathogens11020181","article-title":"Achromobacter spp. in a cohort of non-selected pre- and post-lung transplant recipients","volume":"11","author":"Crone","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.cmi.2025.08.012_bib34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.arbres.2023.05.017","article-title":"Experience with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced disease","volume":"59","author":"Carrasco Hern\u00e1ndez","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.cmi.2025.08.012_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjms.2024.02.001","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on respiratory colonization in an adult cystic fibrosis clinic","volume":"367","author":"Szabo","year":"2024","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.cmi.2025.08.012_bib36","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jcf.2022.09.007","article-title":"Advent of elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis treatment: what consequences on Aspergillus-related diseases? Preliminary insights","volume":"21","author":"Chesnay","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cmi.2025.08.012_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cmi.2025.08.012_bib38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12890-022-01992-2","article-title":"Validation of nasal tracheal aspiration in children with lung disease","volume":"22","author":"Andersen","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.cmi.2025.08.012_bib39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jcf.2024.11.004","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on utilization of routine therapies in cystic fibrosis: Danish nationwide register study","volume":"24","author":"R\u00e5ket","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.cmi.2025.08.012_bib40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.cmi.2025.08.012_bib41","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2025.08.012_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164232","article-title":"Throat swabs and sputum culture as predictors of P. aeruginosa or S. aureus lung colonization in adult cystic fibrosis patients","volume":"11","author":"Seidler","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2025.08.012_bib43","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1038\/s41467-018-05944-5","article-title":"High-resolution in situ transcriptomics of Pseudomonas aeruginosa unveils genotype independent patho-phenotypes in cystic fibrosis lungs","volume":"9","author":"Rossi","year":"2018","journal-title":"Nat Commun"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:26:46Z","timestamp":1772882806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25004082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1198743X25004082"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.08.012","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Change in pulmonary pathogens 3 years after elexacaftor\/tezacaftor\/ivacaftor: an observational study in the Danish cystic fibrosis cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}